Gehringer, F.; Weissinger, S.E.; Swier, L.J.; Möller, P.; Wirth, T.; Ushmorov, A.
FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma. Cancers 2019, 11, 1427.
https://doi.org/10.3390/cancers11101427
AMA Style
Gehringer F, Weissinger SE, Swier LJ, Möller P, Wirth T, Ushmorov A.
FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma. Cancers. 2019; 11(10):1427.
https://doi.org/10.3390/cancers11101427
Chicago/Turabian Style
Gehringer, Franziska, Stephanie E Weissinger, Lotteke JYM Swier, Peter Möller, Thomas Wirth, and Alexey Ushmorov.
2019. "FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma" Cancers 11, no. 10: 1427.
https://doi.org/10.3390/cancers11101427
APA Style
Gehringer, F., Weissinger, S. E., Swier, L. J., Möller, P., Wirth, T., & Ushmorov, A.
(2019). FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma. Cancers, 11(10), 1427.
https://doi.org/10.3390/cancers11101427